United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a...

|About: United Therapeutics Corpora... (UTHR)|By:, SA News Editor

United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a new price target of $48 from $65 by Leerink Swann, which cites generic risk to its treatment of pulmonary arterial hypertension. A recent survey by the firm says "most physicians believe that a minority of their patients are candidates for oral Remodulin."